vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and IAC Inc. (IAC). Click either name above to swap in a different company.

IAC Inc. is the larger business by last-quarter revenue ($646.0M vs $487.7M, roughly 1.3× CLOVER HEALTH INVESTMENTS, CORP.). CLOVER HEALTH INVESTMENTS, CORP. runs the higher net margin — -10.1% vs -11.9%, a 1.8% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (44.7% vs -10.5%). IAC Inc. produced more free cash flow last quarter ($31.4M vs $-69.0M). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (18.6% CAGR vs 1.7%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

IAC Inc. is an American holding company that owns brands worldwide, mostly in media and Internet. The company originated in 1996 as HSN Inc., the holding company of Home Shopping Network and USA Network before changing its name to USA Networks, Inc. in 1999. The firm's television assets then were sold to Vivendi in 2002.

CLOV vs IAC — Head-to-Head

Bigger by revenue
IAC
IAC
1.3× larger
IAC
$646.0M
$487.7M
CLOV
Growing faster (revenue YoY)
CLOV
CLOV
+55.2% gap
CLOV
44.7%
-10.5%
IAC
Higher net margin
CLOV
CLOV
1.8% more per $
CLOV
-10.1%
-11.9%
IAC
More free cash flow
IAC
IAC
$100.3M more FCF
IAC
$31.4M
$-69.0M
CLOV
Faster 2-yr revenue CAGR
CLOV
CLOV
Annualised
CLOV
18.6%
1.7%
IAC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CLOV
CLOV
IAC
IAC
Revenue
$487.7M
$646.0M
Net Profit
$-49.3M
$-76.8M
Gross Margin
69.8%
Operating Margin
-10.1%
-17.5%
Net Margin
-10.1%
-11.9%
Revenue YoY
44.7%
-10.5%
Net Profit YoY
-123.2%
61.4%
EPS (diluted)
$-0.96

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
IAC
IAC
Q4 25
$487.7M
$646.0M
Q3 25
$496.6M
$589.8M
Q2 25
$477.6M
$586.9M
Q1 25
$462.3M
$570.5M
Q4 24
$337.0M
$721.4M
Q3 24
$331.0M
$642.0M
Q2 24
$356.3M
$634.4M
Q1 24
$346.9M
$624.3M
Net Profit
CLOV
CLOV
IAC
IAC
Q4 25
$-49.3M
$-76.8M
Q3 25
$-24.4M
$-21.9M
Q2 25
$-10.6M
$211.5M
Q1 25
$-1.3M
$-216.8M
Q4 24
$-22.1M
$-199.0M
Q3 24
$-9.2M
$-243.7M
Q2 24
$7.4M
$-142.2M
Q1 24
$-19.2M
$45.0M
Gross Margin
CLOV
CLOV
IAC
IAC
Q4 25
69.8%
Q3 25
64.8%
Q2 25
65.6%
Q1 25
64.0%
Q4 24
65.8%
Q3 24
24.5%
62.1%
Q2 24
30.3%
60.1%
Q1 24
23.6%
58.4%
Operating Margin
CLOV
CLOV
IAC
IAC
Q4 25
-10.1%
-17.5%
Q3 25
-4.9%
-3.5%
Q2 25
-2.2%
0.1%
Q1 25
-0.3%
6.3%
Q4 24
-6.4%
6.7%
Q3 24
-2.7%
1.3%
Q2 24
2.0%
-3.4%
Q1 24
-6.5%
-10.2%
Net Margin
CLOV
CLOV
IAC
IAC
Q4 25
-10.1%
-11.9%
Q3 25
-4.9%
-3.7%
Q2 25
-2.2%
36.0%
Q1 25
-0.3%
-38.0%
Q4 24
-6.6%
-27.6%
Q3 24
-2.8%
-38.0%
Q2 24
2.1%
-22.4%
Q1 24
-5.5%
7.2%
EPS (diluted)
CLOV
CLOV
IAC
IAC
Q4 25
$-0.96
Q3 25
$-0.27
Q2 25
$2.57
Q1 25
$-2.64
Q4 24
$-2.36
Q3 24
$-2.93
Q2 24
$-1.71
Q1 24
$0.51

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
IAC
IAC
Cash + ST InvestmentsLiquidity on hand
$78.3M
$960.2M
Total DebtLower is stronger
$1.4B
Stockholders' EquityBook value
$308.7M
$4.7B
Total Assets
$541.0M
$7.1B
Debt / EquityLower = less leverage
0.30×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
IAC
IAC
Q4 25
$78.3M
$960.2M
Q3 25
$1.0B
Q2 25
$1.1B
Q1 25
$1.2B
Q4 24
$194.5M
$1.4B
Q3 24
$288.0M
$1.3B
Q2 24
$254.8M
$1.3B
Q1 24
$208.3M
$1.3B
Total Debt
CLOV
CLOV
IAC
IAC
Q4 25
$1.4B
Q3 25
$1.4B
Q2 25
$1.4B
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
CLOV
CLOV
IAC
IAC
Q4 25
$308.7M
$4.7B
Q3 25
$340.9M
$4.8B
Q2 25
$344.2M
$4.9B
Q1 25
$336.1M
$4.7B
Q4 24
$341.1M
$5.6B
Q3 24
$342.2M
$5.8B
Q2 24
$324.9M
$6.0B
Q1 24
$292.5M
$6.1B
Total Assets
CLOV
CLOV
IAC
IAC
Q4 25
$541.0M
$7.1B
Q3 25
$559.7M
$7.2B
Q2 25
$575.0M
$7.4B
Q1 25
$583.7M
$7.2B
Q4 24
$580.7M
$9.7B
Q3 24
$653.0M
$9.8B
Q2 24
$674.2M
$10.2B
Q1 24
$671.8M
$10.4B
Debt / Equity
CLOV
CLOV
IAC
IAC
Q4 25
0.30×
Q3 25
0.30×
Q2 25
0.30×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
IAC
IAC
Operating Cash FlowLast quarter
$-66.9M
$36.6M
Free Cash FlowOCF − Capex
$-69.0M
$31.4M
FCF MarginFCF / Revenue
-14.1%
4.9%
Capex IntensityCapex / Revenue
0.4%
0.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-69.2M
$44.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
IAC
IAC
Q4 25
$-66.9M
$36.6M
Q3 25
$12.1M
$30.1M
Q2 25
$5.4M
$-2.8M
Q1 25
$-16.3M
$63.0K
Q4 24
$34.8M
$110.1M
Q3 24
$50.0M
$95.3M
Q2 24
$44.8M
$85.0M
Q1 24
$25.9M
$64.1M
Free Cash Flow
CLOV
CLOV
IAC
IAC
Q4 25
$-69.0M
$31.4M
Q3 25
$11.4M
$25.3M
Q2 25
$4.8M
$-7.2M
Q1 25
$-16.5M
$-4.6M
Q4 24
$33.3M
$104.8M
Q3 24
$49.6M
$92.0M
Q2 24
$44.4M
$81.6M
Q1 24
$25.5M
$61.1M
FCF Margin
CLOV
CLOV
IAC
IAC
Q4 25
-14.1%
4.9%
Q3 25
2.3%
4.3%
Q2 25
1.0%
-1.2%
Q1 25
-3.6%
-0.8%
Q4 24
9.9%
14.5%
Q3 24
15.0%
14.3%
Q2 24
12.5%
12.9%
Q1 24
7.3%
9.8%
Capex Intensity
CLOV
CLOV
IAC
IAC
Q4 25
0.4%
0.8%
Q3 25
0.1%
0.8%
Q2 25
0.1%
0.8%
Q1 25
0.0%
0.8%
Q4 24
0.5%
0.7%
Q3 24
0.1%
0.5%
Q2 24
0.1%
0.5%
Q1 24
0.1%
0.5%
Cash Conversion
CLOV
CLOV
IAC
IAC
Q4 25
Q3 25
Q2 25
-0.01×
Q1 25
Q4 24
Q3 24
Q2 24
6.04×
Q1 24
1.42×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLOV
CLOV

Segment breakdown not available.

IAC
IAC

Print$168.5M26%
Performance Marketing$101.2M16%
Care.com$85.7M13%
Subscription$69.5M11%
Licensing And Other$43.8M7%
Consumer Revenue$43.2M7%
Advertising$35.9M6%
Project And Other Print$33.6M5%
Advertising Google$28.9M4%
Newsstand$22.4M3%
Emerging Other$19.6M3%

Related Comparisons